Welcome to our dedicated page for Novanta news (Ticker: NOVT), a resource for investors and traders seeking the latest updates and insights on Novanta stock.
Novanta Inc. (Nasdaq: NOVT) is a global supplier of core technology solutions for medical, life science, and advanced industrial original equipment manufacturers. As a trusted technology partner to medical and advanced technology equipment manufacturers, the company frequently features in news related to its financial performance, capital markets activity, and participation in investor and industry conferences.
News about Novanta often includes quarterly earnings releases and related conference call announcements, where the company reports GAAP results alongside non-GAAP metrics such as Adjusted EBITDA, Adjusted Diluted EPS, and Organic Revenue Growth. These updates provide insight into how its precision medicine, precision manufacturing, medical solutions, robotics and automation, and advanced surgery businesses are performing.
Investors can also expect coverage of capital structure developments, such as the offering and pricing of tangible equity units that combine prepaid stock purchase contracts with senior amortizing notes, as well as amendments to credit agreements and details of senior credit facilities. Announcements about share repurchase authorizations by the Board of Directors are another recurring news theme, reflecting decisions on capital allocation.
In addition, Novanta regularly appears in conference and investor event schedules, including healthcare and industrial conferences hosted by firms such as J.P. Morgan, Baird, Jefferies, and CJS Securities. These events highlight management’s engagement with the investment community and provide forums for discussing strategy and market positioning.
This news page aggregates such items in one place, helping readers follow Novanta’s earnings announcements, financing activities, share repurchase plans, and public presentations over time.
Novanta Inc. (Nasdaq: NOVT), a trusted technology partner to medical and advanced technology equipment manufacturers, has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025.
The company will host a conference call at 10:00 a.m. ET on the same day to discuss the results. Investors can access the call by dialing (888) 346-3959 or join via live webcast through the Events & Presentations page on Novanta's website. An audio replay will be available approximately three hours after the call concludes and remain accessible until June 30, 2025.
Novanta reported its financial results for Q4 and full year 2024. Q4 2024 GAAP revenue increased 13% to $238 million, despite a $2 million unfavorable FX impact. GAAP diluted EPS was $0.46, while adjusted EPS was $0.76. Full year 2024 GAAP revenue rose 8% to $949 million. GAAP diluted EPS was $1.77, and adjusted EPS was $3.08. Adjusted EBITDA for the full year grew 7% to $210 million, and operating cash flow increased 32% to $159 million.
In Q4, organic revenue growth was 3.4%. GAAP operating income was $26.7 million, up from $21.7 million in Q4 2023. GAAP net income was $16.5 million, compared to $12.5 million in Q4 2023. Adjusted EBITDA rose 15% to $52.1 million, and operating cash flow increased 58% to $61.6 million.
For the full year, GAAP operating income was $110.6 million, and GAAP net income was $64.1 million, down from $72.9 million in 2023. Adjusted EBITDA increased to $209.8 million. Net debt was $305.2 million.
For 2025, Novanta projects GAAP revenue of $1 billion, with adjusted EBITDA between $225 million and $235 million, and adjusted EPS between $3.35 and $3.55. Q1 2025 GAAP revenue is expected to be $232 million to $236 million, with adjusted EBITDA between $48 million and $51 million, and adjusted EPS between $0.63 and $0.71.
IDEX (NYSE: IEX) has announced significant changes to its Board of Directors. The company has appointed Stephanie Disher, CEO of Atmus Filtration Technologies, and Matthijs Glastra, Chair and CEO of Novanta Inc., to its Board, effective February 21, 2025. These appointments will increase the Board size from 10 to 12 directors.
Disher will serve on the Nominating and Corporate Governance Committee, while Glastra joins the Audit Committee. Both bring extensive global leadership experience - Disher in finance and operations from her roles at Atmus, Cummins, and BP, and Glastra in international operations, innovation, M&A, and strategy from Novanta and Philips.
Additionally, David Parry and Livingston Satterthwaite will retire from the Board following the 2025 Annual Meeting of Stockholders and will not seek re-election.
Novanta Inc. (Nasdaq: NOVT) has scheduled its fourth quarter and full year 2024 earnings release and conference call for Tuesday, February 25, 2025. The conference call will begin at 10:00 a.m. ET. Investors can access the call by dialing (888) 346-3959 or joining the live webcast through the Events & Presentations page on Novanta's website. The audio webcast replay will be available approximately three hours after the call concludes and will remain accessible until April 21, 2025 on the company's investor relations website.
Novanta (Nasdaq: NOVT), a technology partner specializing in medical and advanced technology equipment manufacturing, has announced its participation in the upcoming CJS Securities 25th Annual New Ideas for the New Year Investor Conference. The virtual event is scheduled for Tuesday, January 14, 2025. This conference represents an opportunity for Novanta's management to present their company's developments and strategies to investors.
Novanta (Nasdaq: NOVT), a technology partner specializing in medical and advanced technology equipment manufacturing, has announced its participation in the J.P. Morgan 43rd Annual Healthcare Conference. The presentation will take place on January 13, 2025, in San Francisco, California. The company will be represented by Chair & CEO Matthijs Glastra and CFO Robert Buckley at this prestigious healthcare industry event.
Novanta (NOVT) reported strong Q3 2024 financial results with GAAP revenue of $244.4 million, up 10.3% year-over-year. The company posted GAAP net income of $19.2 million and diluted EPS of $0.53. Acquisition activities contributed 9.5% to revenue growth, while organic revenue growth was flat. The company's minimally invasive surgery products achieved a book-to-bill ratio of 1.4. For Q4 2024, Novanta expects revenue between $237-242 million and projects full-year 2024 revenue of $948-953 million. The company anticipates organic revenue growth of up to 10% in 2025.
Novanta Inc. (Nasdaq: NOVT), a trusted technology partner for medical and advanced technology equipment manufacturers, has announced an upcoming presentation at the Baird 2024 Global Industrial Conference. The event is scheduled to take place on Wednesday, November 13, 2024, in Chicago, Illinois.
Matthijs Glastra, the Chair & Chief Executive Officer of Novanta, will be presenting at the conference. This presentation offers an opportunity for investors and industry professionals to gain insights into Novanta's operations, strategies, and market position within the industrial technology sector.
Novanta Inc. (Nasdaq: NOVT), a trusted technology partner to medical and advanced technology equipment manufacturers, has announced its plans to release third quarter 2024 results on Tuesday, November 5, 2024. The company will host a conference call at 10:00 a.m. ET on the same day to discuss the results.
Investors can access the call by dialing (888) 346-3959 before the scheduled time. Alternatively, a live webcast will be available on the Events & Presentations page of the Investors section on Novanta's website. An audio replay of the webcast will be accessible approximately three hours after the call concludes and will remain available until Monday, December 30, 2024.
Novanta Inc. (Nasdaq: NOVT) reported its Q2 2024 financial results, showing revenue growth of 2.8% to $235.9 million. The company's GAAP net income was $13.8 million, with diluted EPS of $0.38. Adjusted EBITDA reached $51.1 million, while adjusted diluted EPS was $0.73. Novanta's acquisition activities contributed 8.9% to revenue growth, offsetting a 5.3% decrease in organic revenue. The company generated strong operating cash flow of $41.1 million. For the full year 2024, Novanta expects GAAP revenue of approximately $975 million, representing over 10% growth, with adjusted EBITDA projected between $215-$222 million and adjusted diluted EPS of $3.20-$3.35.